Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-presents-new-scientific-evidence-cosentyx-ankylosing-spondylitis-and-psoriatic-arthritis-patients-eular-2016Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
- https://www.novartis.com/news/media-releases/novartis-combination-therapy-tafinlar-mekinist-demonstrates-overall-survival-benefit-three-year-follow-patients-advanced-melanomaStudy is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of…
- https://www.novartis.com/news/media-releases/novartis-pivotal-data-tafinlar-mekinist-demonstrated-63-percent-overall-response-rate-treating-rare-form-lung-cancerThe median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months Efficacy analyses also presented for INC280 (…
- https://www.novartis.com/news/media-releases/novartis-data-show-more-50-percent-eligible-ph-cml-patients-maintain-treatment-free-remission-tfr-after-stopping-tasignaIn ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >…
- https://www.novartis.com/news/media-releases/novartis-drug-afinitor-receives-eu-approval-treat-certain-types-advanced-gastrointestinal-gi-and-lung-neuroendocrine-tumors-netAfinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Nonfunctional GI and lung NET are…
- https://www.novartis.com/news/media-releases/novartis-highlights-its-strong-foundation-long-term-sustainable-growth-third-meet-novartis-management-eventOutlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights…
- https://www.novartis.com/news/media-releases/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines-agencySandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label…
- https://www.novartis.com/news/media-releases/novartis-entresto-given-strong-class-i-recommendation-both-us-and-eu-heart-failure-guidelines-less-year-after-regulatory-approvalsUS guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated…
- https://www.novartis.com/diseases/paroxysmal-nocturnal-hemoglobinuria-pnh
- https://www.novartis.com/news/media-releases/novartis-enregistre-en-2014-une-forte-augmentation-de-ses-ventes-sa-marge-et-progres-de-son-pipeline-la-transformation-du-portefeuille-concentrera-lentreprise-sur-ses-principales-activitesHausse du chiffre d'affaires net en 2014, avec une forte augmentation de la marge core[1] Hausse du chiffre d'affaires net de 1% (+3% tcc[1])[2] à USD 58,0 milliards en 2014 (-2%, +4% tcc au T4)…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 263
- › Next page